If tau is the stronger correlate of decline, why have anti-amyloid therapies (lecanemab, donanemab) shown clinical benefit while anti-tau therapies have largely failed?

Evidence span

If tau is the stronger correlate of decline, why have anti-amyloid therapies (lecanemab, donanemab) shown clinical benefit while anti-tau therapies have largely failed?

Method & conditions

Evidence type

observational

Method

manual state transition

Conditions

Scope imported from broad Alzheimer's Therapeutics frontier; curator review required.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required